Figure 7
From: Vascularised cardiac spheroids-on-a-chip for testing the toxicity of therapeutics
Impact of vandetanib exposure on the beating of cardiac spheroids in µFCs. CMEF spheroids in suspension and in µFCs were incubated with vandetanib (1 and 10 µM) solutions and compared to empty carrier injection (0.1%DMSO). (A) Beat rates were recorded before therapeutic incubation and over a 2 h period post-incubation. Comparisons are between suspension and device at the same time point. (B) Beat rates presented after normalisation against rates prior incubation. Error bars are standard errors, n ≥ 3. The top dashed red line indicates the level of beat rates prior to exposure to vandetanib. The lower dashed red line highlights the drop in beat rates after exposure to DMSO (Control) 3 min after incubation. For DMSO in device, at least 3 biological repeats were done for each time point. For DMSO in suspension, at 5 biological repeats were done for each time point. For vandetanib 1 µM, 4 biological repeats were done for each time point and each condition (device and suspension). For vandetanib 10 µM in device, 3 biological repeats were done for each time point. For vandetanib 10 µM in suspension, 4 biological repeats were done for each time point. One technical repeat was done for each condition as one spheroid was analysed per repeat.
